Live UTI Free’s Post

Point-of-care testing (POCT) is transforming emergency department care by delivering rapid, actionable results right at the bedside. In high-pressure environments where every second counts, POCT enables clinicians to make quicker, more informed decisions, ultimately improving patient outcomes and streamlining workflows. Whether it’s for diagnosing conditions like traumatic brain injuries or monitoring critical vitals, the ability to test and receive results on the spot reduces wait times, enhances patient care, and optimises resource utilisation. As healthcare continues to evolve, the importance of POCT in emergency settings cannot be overstated—it’s a vital tool for delivering efficient, effective care when it matters most. Traumatic brain injuries (TBI) present a significant challenge in emergency departments, where rapid and accurate diagnosis is crucial for effective treatment. Traditional methods, like CT scans, can be time-consuming, costly, and not always immediately available, leading to delays in critical care. This is where point-of-care testing (POCT) is making a profound impact, especially with the emerging role of microRNA (miRNA) biomarkers. miRNA-based POCT for TBI offers a groundbreaking approach to quickly assess brain injury severity right at the bedside. miRNAs are small, non-coding RNA molecules that play a critical role in gene regulation, and certain miRNAs have been identified as reliable biomarkers for TBI. These miRNA biomarkers can be detected through minimally invasive tests, providing real-time insights into the extent of brain injury. The integration of micro RNA (miRNA) POCT in emergency settings could revolutionise TBI management. By enabling rapid, accurate diagnosis, clinicians can make timely decisions about patient care, potentially reducing the need for unnecessary imaging and improving patient outcomes. Additionally, miRNA POCT can help in identifying patients who may otherwise be at risk of being underdiagnosed, ensuring that even subtle brain injuries are promptly addressed. Ultimately, personalised prescription and safe return to activity (RTA). As we continue to explore and develop miRNA-based POCT for TBI, the potential to enhance patient care, reduce costs, and streamline emergency department workflows is immense. This innovative approach represents a significant advancement in the way we diagnose and treat TBIs, offering hope for faster, more effective interventions when they are needed most. #tbi #diagnostics #POCT #miRNA GLIA Diagnostics Pty Ltd

Great collaborative effort led by Koh Jin Hean and Li Feng Tan synthesizing the literature on head and neck CT-derived sarcopenia biomarkers across various disease cohorts including #stroke, #trauma, and #brain #aneurysms. CT-defined sarcopenia is predictive of increased mortality and adverse outcomes in medical and surgical patients.  Measurement and early identification of sarcopenia in vulnerable patients allows for enhanced prognostication and targeted allocation of care to mitigate adverse outcomes. Frederick Koh Andrew Makmur Jim Hallinan leonard yeo Ching-Hui Sia Check out the full study here: 📊💡

After 6 years, the journey of the OptimAT study (NCT03477331) has finally come to an end with 4/6 antithrombotics reaching the target of 100 recruited patients. This prospective study aims to validate PopPK and PBPK models for direct oral anticoagulants and P2Y12 inhibitors in a cohort of hospitalised patients HUG - Hopitaux Universitaires de Genève. Clinical events were also followed up for up to two years. All patients were phenotyped and genotyped for CYP450 and a large biobank was established. The ultimate goal is to provide clinicians with a tool to identify a priori patients at risk of under- or overdosing and clinical events (e.g. bleeding). Thanks to all the people who made this project possible: Jean-Luc Reny Youssef Daali Caroline Samer Jules Desmeules and our wonderful national Pierre Fontana Frédéric Gaspar Chantal Csajka Monia Guidi Camille Lenoir Victoria Rollason and international collaborators Brahim Achour Amin Rostami-Hodjegan. And a special thanks to our clinical research coordinator Pauline Gosselin without whom none of this would have been possible. Several projects derived from this cohort are in progress and will be released in the coming months. And if you missed the last ones: 🔶Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side https://lnkd.in/eGJVpFhq 🔶 Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study https://lnkd.in/efEKPVxm 🔶 Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities https://lnkd.in/e_pec_vc 🔶 Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting https://lnkd.in/eqPVYhdw #research #medicine #health #personalisation #pharmacology

📃Scientific paper: Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study Abstract: Purpose Data on the long-term safety and effectiveness of drug-coated balloons (DCBs) for the treatment of long femoropopliteal atherosclerotic lesions in the real-world setting are rare. This study reports 3 year and 5 year outcomes of the pre-specified 150 mm balloon sub-cohort of the IN.PACT Global Study. Methods The IN.PACT Global Study was a prospective, multicentre, international, single-arm study evaluating the performance of the IN.PACT Admiral DCB in real-world patients with femoropopliteal atherosclerotic disease. This pre-specified 150 mm DCB cohort analysis comprised 107 participants (111 lesions) with all target lesions treated with at least one 150 mm DCB. Results Mean lesion length was 20.3 ± 9.2 cm; 18.0% had in-stent restenosis, 58.6% were totally occluded, and 17.1% were severely calcified. Through 60 months, the Kaplan–Meier estimate of freedom from clinically driven target lesion revascularization (CD-TLR) was 72.7% [95% confidence interval (CI):62.4%–80.5%]. The safety composite endpoint (freedom from device/procedure-related death through 30 days; freedom from target limb major amputation and clinically driven target vessel revascularization through 5 years) was 70.5%. The cumulative incidence of major amputation was 1.0% and all-cause mortality was 18.4%. Freedom from CD-TLR rates in the provisional stented and non-stented subgroups through 36 months were 64.0% [95% CI: 46.1%–77.3%] and 81.9% [95% CI: 69.7%–89.6%] (log-rank p  = 0.074), respec... Continued on ES/IODE ➡️ https://etcse.fr/VNvr ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Thrilled to share our latest review, just published in #MatrixBiology 💫 Collaborating with leading experts in myocardial fibrosis— Ida Gjervold Lunde, Sophie Van Linthout, Javier Diez and Arantxa González Miqueo PhD FHFA —has been both an honor and a pleasure 🙌 In this comprehensive review, we delve into the mechanisms of myocardial fibrosis from a #Matrix perspective, with a focus on clinical detection, current treatments, and emerging targets 🔬💊 Key Highlights: 🚨 Myocardial fibrosis, a common denominator in heart diseases, predicts poor outcomes and mortality 💔 The absence of specific clinical biomarkers and therapies for fibrosis remains a critical unmet medical need 👉 Enhancing our understanding of cardiac extracellular matrix mechanisms is crucial for improving clinical outcomes ❤️ Innovative strategies targeting the #ECM and cardiac #fibroblasts hold promise for future therapies. #CVD #fibrosis #ECM #heartfailure #heartdisease https://lnkd.in/dAN-UwjZ

🔍 Exciting new study shows the potential of optical coherence tomography (OCT) imaging as a non-invasive tool for monitoring kidney injury in chronic kidney disease (CKD) patients. The research revealed that OCT metrics, including retinal and choroidal thinning, were linked to kidney function decline and histological kidney injury. This suggests that OCT imaging could serve as a valuable biomarker for predicting outcomes in CKD patients. #kidneydisease #OCTImaging #medicalresearch 📊👁️ More about this study can be found here: https://lnkd.in/ebQ58CAA

🔍 𝐋𝐚𝐬𝐭 𝐦𝐨𝐧𝐭𝐡, 𝐭𝐡𝐞 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐟𝐫𝐨𝐦 𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲’𝐬 𝐥𝐚𝐫𝐠𝐞 𝐑𝐖𝐄 𝐬𝐭𝐮𝐝𝐲 𝐮𝐬𝐢𝐧𝐠 𝐃𝐚𝐧𝐢𝐬𝐡 𝐑𝐖𝐃 𝐰𝐚𝐬 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 𝐖𝐂𝐎-𝐈𝐎𝐅-𝐄𝐒𝐂𝐄𝐎. “This cohort patient study provides an invaluable blueprint to inform future treatment decision-making and support optimal use of romosozumab in clinical practice, both in Denmark and across Europe,” said Emmanuel Caeymaex, Executive Vice President, Immunology and U.S. Solutions at UCB. “The study findings enable us to understand the use of romosozumab as a treatment option in the real world and demonstrate its potential in closing the treatment gap for patients at high risk of fracture.” The retrospective cohort study in Denmark showcased the significance of romosozumab in routine clinical practice, particularly among postmenopausal women at high fracture risk. Notably, patients in the romosozumab cohort had experienced hip and spine fractures prior to treatment, emphasizing the critical need for effective intervention. Osteoporosis imposes a significant global burden, yet many remain untreated following fragility fractures. By leveraging real-world data, we're advancing towards closing this treatment gap and improving patient care. For further details, feel free to reach out to us. Let's continue driving progress in osteoporosis management together! #OsteoporosisAwareness #HealthcareInnovation #Romosozumab #PatientCare Quantify Research info@quantifyresearch.com www.quantifyresearch.com

JACC-HF Cardiogenic shock (CS) patients remain at 30% to 60% in-hospital mortality despite therapeutic innovations. Heterogeneity of CS has complicated clinical trial design. Recently, 3 distinct CS phenotypes were identified in the CSWG (Cardiogenic Shock Working Group) registry version 1 (V1) and external cohorts: I, “noncongested;” II, “cardiorenal;” and III, “cardiometabolic” shock.

Can patient access to safe and effective medical technologies in the NHS be accelerated? That’s the pivotal question this groundbreaking pilot is aiming to answer. ⚠📢 Currently, it can take over a decade for a new diagnostic test or medical device to be adopted at scale in the NHS. 💡 This initiative will enhance communication between NICE, MHRA, devolved administrations and industry to help make the complex evidence generation process for new technologies as efficient as possible, with the ultimate hope/aim of improving patient outcomes. 💡 The 8 technologies chosen for this pilot address many of the most common, debilitating, and deadly diseases facing us in the UK and beyond: liver cancer, Alzheimer’s disease (the UK’s biggest killer in 2022), stroke, chronic obstructive pulmonary disease (COPD), multiple sclerosis, neutropenia, and sepsis. 🙏 Such an honor to be one of the chosen companies. I hope we can help to make impactful changes that translate into improved patient outcomes. #medicalinnovation #diagnostics #medtechinnovation Roche Diagnostics UK & Ireland

𝐀𝐧𝐠𝐢𝐨𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐬 𝐏𝐄 𝐓𝐫𝐢𝐚𝐥 𝐄𝐧𝐫𝐨𝐥𝐥𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐀𝐥𝐩𝐡𝐚𝐕𝐚𝐜 𝐒𝐲𝐬𝐭𝐞𝐦 AngioDynamics, a prominent medical technology company dedicated to enhancing blood flow, expanding cancer treatment options, and improving patient quality of life, has successfully concluded patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). This clinical study focuses on assessing the safety and efficacy of AngioDynamics’ AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in treating acute intermediate-risk pulmonary embolism (PE). Pulmonary embolism affects around 900,000 people in the United States annually and can be life-threatening. Patients with submassive or intermediate-risk PE, representing a significant portion of those hospitalized, have a mortality rate of 3 to 14%. The APEX-AV Study contributes valuable insights to enhance treatment outcomes in this critical area of healthcare. Juan Carlos Serna, AngioDynamics’ Senior Vice President of Clinical and Scientific Affairs. “We thank The PERT Consortium™, including our enrolling partners, for its commitment to generating robust clinical evidence to help address the needs of this patient population.” The findings plan to assess the performance of the AlphaVac F1885 System in reducing thrombus burden and improving right ventricular function, Click to learn more: https://lnkd.in/eM8hb3i5 #mededgemea #PERTConsortium #thrombus #acutepulmonary #AngioDynamics